• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by TriSalus Life Sciences Inc.

    12/4/24 4:00:06 PM ET
    $TLSI
    Medical Specialities
    Health Care
    Get the next $TLSI alert in real time by email
    SC 13G 1 tm2430131d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

     

    TRISALUS LIFE SCIENCES, INC.

    (Name of Issuer)

     

    Common Stock, Par Value $0.0001 per share

    (Title of Class of Securities)

     

    89680M101

    (CUSIP Number)

     

    November 26, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 89680M101  Page 1 of 1

     

    1

    NAMES OF REPORTING PERSONS

    James J. Pallotta

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) ¨ (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON

    WITH

    5

    SOLE VOTING POWER(1)

    1,909,729 shares

    6

    SHARED VOTING POWER

    -0-

    7

    SOLE DISPOSITIVE POWER(1)

    1,909,729 shares

    8

    SHARED DISPOSITIVE POWER

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,909,729 (1) shares

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.24% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN

     

    (1)Includes 114,268 shares underlying warrants exercisable into shares of the issuer’s common stock.

     

    (2)The percentages used herein are calculated based upon 30,493,137 shares of the issuer’s common stock outstanding as of November 8, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2024, plus 114,268 shares underlying warrants exercisable into shares of the issuer’s common stock.

     

     

     

     

    Item 1(a)Name of Issuer:

     

    TriSalus Life Sciences, Inc.

     

    Item 1(b)Address of Issuer’s Principal Executive Offices:

     

    6272 W. 91st Ave., Westminster, Colorado 80031

     

    Item 2(a)Name of Person Filing:

     

    James J. Pallotta

     

    Item 2(b)Address of Principal Business Office or, if none, Residence:

     

    2340 Collins Avenue, 5th Floor, Miami Beach, Florida 33139

     

    Item 2(c)Citizenship:

     

    United States

     

    Item 2(d)Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share

     

    Item 2(e)CUSIP No.:

     

    89680M101

     

    Item 3If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable

     

     

     

    Item 4Ownership:

     

    (a)Amount beneficially owned: See Row 9 of the cover page.

     

    (b)Percent of class: See Row 11 of the cover page.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or direct the vote: See Row 5 of the cover page.

     

    (ii)Shared power to vote or direct the vote: See Row 6 of the cover page.

     

    (iii)Sole power to dispose or direct the disposition: See Row 7 of the cover page.

     

    (iv)Shared power to dispose or direct the disposition: See Row 8 of the cover page.

     

    Item 5Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

     

    Item 6Ownership of More Than Five Percent on Behalf of Another Person:

     

    Not applicable

     

    Item 7Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Not applicable

     

    Item 8Identification and Classification of Members of the Group:

     

    Not applicable

     

    Item 9Notice of Dissolution of Group:

     

    Not applicable

     

    Item 10Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

           
          Date: December 4, 2024
         
         
      By: /s/ James J. Pallotta
          Name: James J. Pallotta

     

     

     

     

     

     

     

    Get the next $TLSI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TLSI

    DatePrice TargetRatingAnalyst
    2/13/2025Buy
    Lake Street
    12/17/2024$10.00Overweight
    Cantor Fitzgerald
    11/11/2024$11.00Buy
    ROTH MKM
    10/25/2024$12.50Outperform
    Northland Capital
    9/16/2024$10.00Outperform
    Oppenheimer
    5/30/2024$12.00Buy
    Canaccord Genuity
    More analyst ratings

    $TLSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on TriSalus Life Sciences

      Lake Street initiated coverage of TriSalus Life Sciences with a rating of Buy

      2/13/25 8:48:50 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • Cantor Fitzgerald initiated coverage on TriSalus Life Sciences with a new price target

      Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with a rating of Overweight and set a new price target of $10.00

      12/17/24 8:31:30 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • ROTH MKM initiated coverage on TriSalus Life Sciences with a new price target

      ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00

      11/11/24 7:48:55 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

      TriSalus Life Sciences® Inc. (NASDAQ:TLSI), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy ("TriSalus" or the "Company"), today announced that it has commenced an exchange offer and consent solicitation involving its Series A Convertible Preferred Stock (the "Preferred Stock") identified in the Prospectus/Offer to Exchange (as defined below). TriSalus is committed to simplifying its capital structure and reducing the potential impact of dilution from its Preferred Stock. By exchanging outstanding shares of Preferred Stock for common stock, the Company eliminates complex capital la

      6/23/25 5:30:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System

      TriSalus Life Sciences®, Inc. ("TriSalus" or the "Company") (NASDAQ:TLSI), which seeks to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies and our investigational immunotherapy, is excited to announce the launch of the TriNav® FLX Infusion System, the latest addition to the TriNav Portfolio. TriNav FLX, with enhanced trackability, significantly expands our existing portfolio of TriNav products, offering Interventional Radiologists enhanced trackability and more options to select the right product for the right patient1. The TriNav FLX Infusion System retains the same trusted Pressure-Enabled Drug DeliveryTM

      6/4/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

      David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1, 2025 Current CFO James E. Young steps down; Dan Giordano, Vice President of Finance, to serve as acting CFO during transition period TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of David B. Patience as Chief Financial Officer, effective July 1, 2025. Mr. Patience succeeds James Young, who stepped down for personal reasons effec

      5/30/25 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Patience David

      3 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      7/10/25 4:53:34 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Desai Arjun Jj

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      6/27/25 4:29:54 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Gordon Gary B.

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      6/27/25 4:26:56 PM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by TriSalus Life Sciences Inc.

      SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      12/4/24 4:00:06 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by TriSalus Life Sciences Inc.

      SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

      10/21/24 8:25:05 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Leadership Updates

    Live Leadership Updates

    See more
    • TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

      David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1, 2025 Current CFO James E. Young steps down; Dan Giordano, Vice President of Finance, to serve as acting CFO during transition period TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of David B. Patience as Chief Financial Officer, effective July 1, 2025. Mr. Patience succeeds James Young, who stepped down for personal reasons effec

      5/30/25 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Announces Key Appointments to Board of Directors

      HealthCare Industry Veterans William Valle and Gary Gordon, M.D. add Strategic Expertise in Medical Devices, Reimbursement, and Pancreatic Cancers TriSalus Life Sciences® Inc. (NASDAQ:TLSI), a biomedical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies and its investigational immunotherapy, today announced the appointment of two distinguished HealthCare Industry veterans to its Board of Directors. Mr. William J. Valle and Gary B. Gordon, M.D., Ph.D., joined the Company's Board of Directors, effective as of January 29, 2025. "We are thrilled to welcome William Valle and Dr. Ga

      2/3/25 4:05:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Announces Leadership Changes

      James Young Appointed Chief Financial Officer, Richard Marshak Appointed Chief Commercial Officer, Jodi Devlin Appointed Chief of Clinical Strategy and Operations TriSalus Life Sciences, Inc., (NASDAQ:TLSI), an oncology company dedicated to improving outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and our investigational immunotherapy, today announced key updates to its executive leadership team. James (Jim) Young, who previously served as the Company's Senior Vice President of Investor Relations and Treasurer, has been appointed as the Company's Chief Financial Officer. In this role, Mr. Young succeeds Sean Murp

      1/8/25 8:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Young James Emmett bought $33,900 worth of shares (6,000 units at $5.65) (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      2/6/25 6:09:01 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T bought $51,754 worth of shares (10,040 units at $5.15), increasing direct ownership by 2% to 444,259 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/31/25 5:54:39 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Szela Mary T was granted 40,000 shares and bought $50,303 worth of shares (9,542 units at $5.27), increasing direct ownership by 13% to 434,219 units (SEC Form 4)

      4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

      1/29/25 6:15:05 PM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    SEC Filings

    See more
    • Amendment: SEC Form S-4/A filed by TriSalus Life Sciences Inc.

      S-4/A - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      7/11/25 5:00:27 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      6/23/25 5:29:06 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • SEC Form S-4 filed by TriSalus Life Sciences Inc.

      S-4 - TriSalus Life Sciences, Inc. (0001826667) (Filer)

      6/23/25 5:28:01 PM ET
      $TLSI
      Medical Specialities
      Health Care

    $TLSI
    Financials

    Live finance-specific insights

    See more
    • TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

      TriSalus Life Sciences® Inc. (NASDAQ:TLSI), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy ("TriSalus" or the "Company"), today announced that it has commenced an exchange offer and consent solicitation involving its Series A Convertible Preferred Stock (the "Preferred Stock") identified in the Prospectus/Offer to Exchange (as defined below). TriSalus is committed to simplifying its capital structure and reducing the potential impact of dilution from its Preferred Stock. By exchanging outstanding shares of Preferred Stock for common stock, the Company eliminates complex capital la

      6/23/25 5:30:00 PM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance

      Company delivers 42% revenue growth year-over-year and strengthens balance sheet with $22 million gross proceeds from recent private placement Expands commercial footprint, and invests further in new applications for TriNav already in use Updates 2025 guidance to reflect strategic investment in our core liver market and new applications for PEDD Company to Host Conference Call and Webcast today at 8:00am ET TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results fo

      5/15/25 7:00:00 AM ET
      $TLSI
      Medical Specialities
      Health Care
    • TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call

      Conference Call and Webcast Scheduled for Thursday May 15, 2025 at 8:00 AM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, announced today that it will host a conference call and webcast on Thursday May 15, 2025 at 8:00 AM eastern time to discuss its financial results for the quarter ended March 31, 2025. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the web

      5/12/25 4:30:00 PM ET
      $TLSI
      Medical Specialities
      Health Care